Is Esperion Therapeutics, Inc. (ESPR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 45.8% / 30% | 22.3% / 30% | 12.3% / 30% | 14.11% / 5% | ✗ NOT HALAL |
| DJIM | 45.8% / 33% | 22.3% / 33% | 12.3% / 33% | 14.11% / 5% | ✗ NOT HALAL |
| MSCI | 86.6% / 33% | 42.1% / 33% | 23.3% / 33% | 14.11% / 5% | ✗ NOT HALAL |
| S&P | 45.8% / 33% | 22.3% / 33% | 12.3% / 33% | 14.11% / 5% | ✗ NOT HALAL |
| FTSE | 86.6% / 33% | 42.1% / 33% | 23.3% / 50% | 14.11% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 56.1% | |
| Operating Margin | 50.6% | |
| Net Margin | -5.6% | |
| Return on Assets (ROA) | 9.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$13M |
| Free Cash Flow | -$13M |
| Total Debt | $252M |
| Current Ratio | 1.5 |
| Total Assets | $466M |
Price & Trading
| Last Close | $2.85 |
| 50-Day MA | $3.10 |
| 200-Day MA | $2.66 |
| Avg Volume | 4.9M |
| Beta | 1.1 |
|
52-Week Range
$0.69
| |
About Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Esperion Therapeutics, Inc. (ESPR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Esperion Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Esperion Therapeutics, Inc.'s debt ratio?
Esperion Therapeutics, Inc.'s debt ratio is 45.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 86.6%.
What are Esperion Therapeutics, Inc.'s key financial metrics?
Esperion Therapeutics, Inc. has a market capitalization of $704M, and revenue of $403M. The company maintains a gross margin of 56.1% and a net margin of -5.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.